Assessment of I-125 seed implant accuracy when using the live-planning technique for low dose rate prostate brachytherapy by Joshua Moorrees et al.
Moorrees et al. Radiation Oncology 2012, 7:196
http://www.ro-journal.com/content/7/1/196RESEARCH Open AccessAssessment of I-125 seed implant accuracy when
using the live-planning technique for low dose
rate prostate brachytherapy
Joshua Moorrees1*, John M Lawson1 and Loredana G Marcu1,2,3Abstract
Background: Low risk prostate cancers are commonly treated with low dose rate (LDR) brachytherapy involving
I-125 seeds. The implementation of a ‘live-planning’ technique at the Royal Adelaide Hospital (RAH) in 2007 enabled
the completion of the whole procedure (i.e. scanning, planning and implant) in one sitting. ‘Live-planning’ has the
advantage of a more reliable delivery of the planned treatment compared to the ‘traditional pre-plan’ technique
(where patient is scanned and planned in the weeks prior to implant). During live planning, the actual implanted
needle positions are updated real-time on the treatment planning system and the dosimetry is automatically
recalculated. The aim of this investigation was to assess the differences and clinical relevance between the planned
dosimetry and the updated real-time implant dosimetry.
Methods: A number of 162 patients were included in this dosimetric study. A paired t-test was performed on the
D90, V100, V150 and V200 target parameters and the differences between the planned and implanted dose
distributions were analysed. Similarly, dosimetric differences for the organs at risk (OAR) were also evaluated.
Results: Small differences between the primary dosimetric parameters for the target were found. Still, the incidence
of hotspots was increased with approximately 20% for V200. Statistically significant increases were observed in the
doses delivered to the OAR between the planned and implanted data; however, these increases were consistently
below 3% thus probably without clinical consequences.
Conclusions: The current study assessed the accuracy of prostate implants with I-125 seeds when compared to
initial plans. The results confirmed the precision of the implant technique which RAH has in place. Nevertheless,
geographical misses, anatomical restrictions and needle displacements during implant can have repercussions for
centres without live-planning option if dosimetric changes are not taken into consideration.
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A common treatment option for low grade prostate can-
cers is low dose rate (LDR) seed brachytherapy. It is
usually employed as a monotherapy. Early developments
of this treatment technique would implant the seeds into
the prostate via retropubic surgery. This was later im-
proved so that the seeds were implanted via the peri-
neum without the need for surgery [1]. This procedure
is done by placing the seeds into large gauge needles* Correspondence: joshua.moorrees@health.sa.gov.au
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reproduction in any medium, provided the orwhich are then inserted to the required depth before the
seeds are deployed as the needle is withdrawn. To guide
the placement of these seeds some form of image gui-
dance is typically employed. The most commonly used is
a combination of ultrasound (US) and fluoroscopy, where
the ultrasound imaging is achieved via a trans-rectal ul-
trasound (TRUS) probe.
LDR seed brachytherapy has been performed at the
Royal Adelaide Hospital (RAH) since September 2004.
Initially the two step treatment technique was employed
where the patient had a TRUS volume study on a sepa-
rate day to the implant. The TRUS scan enabled the as-
sessment of prostate volume (prostate volumes rangingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 LDR brachytherapy implant workflow with one step live planning technique (highlighted in bold are the two dosimetry data
recording points).
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images for contouring and treatment planning. The time
gap between the TRUS scan and the seed implant was
usually 4 weeks. On the morning, prior to the implant
the needles were manually loaded with the planned seed
configurations. These needles were then implanted after
aligning the planning US images of the prostate with
the live US images of the prostate as seen on the im-
plant day.
However, the time gap between the TRUS scan and
the implant procedure was shown to lead to suboptimal
consequences due to difficulties in reproducing the pa-
tient alignment. Often it was quite difficult to align the
planning US images with the treatment images. This
challenge was possibly caused by several factors, such as:
(1) changes in patient’s anatomy between the two scans;
(2) changes in patient positioning on the operating couch.
Thus the delivered seed dosimetry was likely to be signi-
ficantly different from the initially planned one [2]. To
eliminate this problem and, at the same time, to optimise
treatment flow, the quality of the implant and hence treat-
ment outcome, it was decided to move to a one step live
planning technique. In a one step live planning techniqueTable 1 Mean values for D90, V100, V150 and V200 for
the prostate along with the associated standard
deviations
Dosimetry Parameter Planned St Dev Implanted St Dev
D90 (Gy) 175.5 9.6 177.7 10.5
V100 (%) 97.9 1.6 97.9 1.5
V150 (%) 64.1 7.3 66.5 7.9
V200 (%) 21.6 5.9 26.1 7.3the TRUS scan and implant are performed on the same
day, significantly reducing the chance for movement and
the changes in prostate position between pre-implant
TRUS and live-implant.
The treatment procedure on the day is as follows: First
the patient in anaesthetised, catheterised and placed in-
to stirrups. Next, an ultrasound scan (BK Medical Flex
Focus 1202–400 US mated with Nucletron SPOT PROTM
Version 3.1 TPS) is taken of the prostate upon which
the prostate, PTV and OAR are contoured by both the
urologist and radiation oncologist in consultation with
each other. In most cases the urethra is both identified
and contoured through the use of a contrast medium
(aerated jelly) which is injected into the catheter. The
visualised catheter (5 mm diameter) is then taken as
being representative of the urethral volume. It should
be noted that patients who are eligible to be treated via
LDR seeds are generally not given androgen deprivation
therapy (ADT) prior to the treatment day. A small num-
ber (~5%) are given ADT in order to bring the prostate
down to a more manageable size. Literature suggests
that shrinkage of around 30% is achieved through the
use of ADT and the maximum shrinkage occurs after a
period of three months [3].Table 2 Percent differences and statistics for target data
Dosimetry Parameter Mean % Diff t test score P value
D90 1.24 2.87 0.0047
V100 0.09 1.00 0.3209
V150 3.81 5.70 0.0001
V200 20.81 10.95 0.0001
Figure 2 Distribution of prostate D90 values for planned and implanted dosimetry.
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physicist or radiation therapist) will create a plan for the
distribution of seeds within the prostate using the
Nucletron SPOT Pro system and a modified uniform
loading of seeds [4,5]. After treatment plan optimisation
and approval, pre-loaded needles (Oncura Rapid Strand
RX) are inserted by the urologist. The seeds are then
deployed to their respective positions as indicated by
the plan under fluoroscopic and ultrasound guidance.
Anchor needles (or fixation needles) are not used at our
centre. However all needles of the same retraction dis-
tance (relative to the prostate base plane) are inserted
and then aligned (with US and fluoroscopy guidance)
prior to seed deployment. At each retraction the prostate
base plane is checked and amendments made if necessary
again prior to seed deployment. After the completion of
the planned implant the radiation oncologist will inspect
the plan on the TPS (using the dosimetry from the liveFigure 3 Distribution of prostate V100 values for planned and implanupdates of the actual implanted seed positions), plus
check the ultrasound and fluoroscopic images, to deter-
mine if the implant dose coverage is satisfactory. If there
were any gaps in the dose coverage of the target the radi-
ation oncologist may request more seeds to be implanted
at a given location within the prostate by the urologist.
The final quality of the implant is assessed via post
implant dosimetry. In our centre, post implant dosimetry
is completed based on US-CT image co-registration,
with the pelvic CT scan taken on day 0 or 1 after the
implant. Details on post implant dosimetry technique
and results have been recently published [6]. According
to the latest ABS guidelines [7] the post implant dosim-
etry (PID) is considered to be a mandatory component of
the implant’s quality assurance and should be undertaken
within 60 days of the implant. While CT-MR fusion-
based PID is recommended, CT-based PID is also con-
sidered acceptable.ted dosimetry.
Figure 4 Distribution of prostate V150 values for planned and implanted dosimetry.
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medical physicist will have performed an independent
assay of the seeds used to ensure the correct activity is
used by the TPS. Initially for this technique the needles
were manually pre-loaded on site prior to implant, but
later we moved to purchasing manufacturer pre-loaded
needles. In each case a set of generic seed-needle confi-
gurations were determined from analysing the seed con-
figurations used for previous implants. The large number
of seeds ordered per patient (110 seeds) allow ample seed
configuration combinations to be pre-loaded.
The SPOT Pro planning software used at the RAH
allows the user to update the location of the implanted
needles in real-time on the treatment planning system
and hence automatically recalculate the plan dosimetry,
to accurately reflect what was actually implanted. This isFigure 5 Distribution of prostate V200 values for planned and implanimportant, as the theoretically planned grid positions
might not always be practically attainable. There are a
few factors which can possibly impede the perfect repro-
duction of the treatment plan:
 Operator-related: needles can miss the planned grid
position by a few millimetres, so they do not exactly
end up where the implanting physician intended
them to go. Though the error is usually small,
overall it contributes to the difference between the
planned and implanted dosimetry.
 Patient anatomy-related: there are situations
when the physician may need to implant at
another grid position than the planned one due
to interference such as pubic arch. Calcifications
inside the prostate gland could also lead toted dosimetry.
Table 3 Mean values for D90, V100, V150 and V200 for
the PTV along with the associated standard deviations
Dosimetry Parameter Planned St Dev Implanted St Dev
D90 (Gy) 168.0 8.0 169.1 10.3
V100 (%) 96.6 1.7 96.6 1.8
V150 (%) 60.2 6.7 62.4 7.4
V200 (%) 20.0 5.1 24.0 6.3
Table 5 Mean values for D10 and D30 for the urethra
along with the associated standard deviations
Dosimetry Parameter Planned St Dev Implanted St Dev
D10 (Gy) 190.6 11.2 196.2 17.1
D30 (Gy) 183.3 10.9 188.2 14.2
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adjustments in needle positions.
 Prostate gland-related: small changes in the prostate
glad volume during implant due to swelling (from
oedema) might influence the decision of needle
placement.
These offsets (both small and large) could potentially
add up to give a significantly different dosimetry to that
which was initially planned and approved.
The current work will identify any significant diffe-
rences for the main dosimetric parameters used in the
reporting of LDR prostate treatments when comparing
the planned dosimetry and the final updated real-time
implant dosimetry.Methods
This report analysed the dosimetry data for all patients
treated since the inception of the ‘live planning’ tech-
nique at the RAH, which amounted to 162 patients.
Given that the LDR seed implant programme at RAH
started in 2004 and that the 2 step live planning proced-
ure with manufacture pre-loaded needles did not start
until Nov 2007, it was felt that during the studied period
all staff involved in prostate brachytherapy were experi-
enced in the procedure. As such, this data should be
considered to be representative of a well established
program. The prescribed dose to the target volume is
145 Gy and the average activity per seed is 0.395mCi,
with an average of 70 seeds being implanted per patient.
The LDR brachytherapy implant workflow during this
period is represented in Figure 1. Of note here are the
two dosimetry data recording points, i.e. (1) prior to im-
plantation and (2) after the completion of the implant
and final plan analysis review. These are the two points
at which data was collected and analysed for this study.Table 4 Percent differences and statistics for PTV data
Dosimetry Parameter Mean % Diff t test score P value
D90 0.61 1.74 0.0842
V100 0.07 0.68 0.4990
V150 3.67 4.95 0.0001
V200 20.47 11.30 0.0001The first will be termed the ‘planned’ dosimetry and the
second the ‘implanted’ dosimetry.
Contour delineation for the prostate target and organs
at risk was performed on the TRUS transverse images,
where the prostate is defined as the clinical target volume
(CTV); the PTV includes the CTV plus treatment mar-
gins of 3–5 mm (depending on the patient’s pathology);
and the OAR include the prostatic urethra and anterior
rectal wall. For the prostate and PTV the dosimetric
parameters analysed were the following: (1) the dose
received by 90% of the relative volume (D90), (2) the
relative volume to receive 100% of reference dose (V100),
(3) the relative volume to receive 150% of the reference
dose (V150) and (4) the relative volume to receive 200%
of the reference dose (V200). These parameters offer
both a good representation of the prostate and PTV
coverage (via D90 and V100) and the incidence of ‘hot
spots’ with V200 and V150. Based on recommendations
for reporting from GEC-ESTRO the dosimetric para-
meters analysed for urethra were D10 and D30 while for
rectum were the dose received by a volume of 2cc of the
prostate (D2cc) and the dose received by a very small
volume (D0.1cc) [8].
To determine if there is any statistically significant dif-
ference between the planned and implanted dosimetric
parameters a paired t test was performed on the two
samples. The mean percent difference between the two
data sets was also determined along with the standard
deviation of these differences.
Results and discussion
The results obtained using the methodology outlined
previously were divided into two sections: one for the
treated volumes, i.e. prostate and PTV, and the other for
the OAR. It should be noted that these mean difference
and standard deviation are in terms of percent difference
relative to the planned dosimetry.
Prostate and PTV
First the average values and standard deviations for each
of the dosimetry parameters can be seen in Table 1 forTable 6 Percent differences and statistics for urethra data
Dosimetry Parameter Mean % Diff t test score P value
D10 2.90 5.06 0.0001
D30 2.64 5.45 0.0001
Figure 6 Distribution of urethra D10 values for planned and implanted dosimetry.
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an increase in all three parameters although this increase
is negligible for V100.
Table 2 shows the mean for the differences between
the planned and implanted dosimetry data shown in
Table 1 as well as the statistical data from the paired
t test.
A slightly significant difference in D90 between the
planned and implanted dose distribution is observed,
however the most significant difference for the target
itself is in V150 and V200. For these parameters there
is approximately a 4% and 20% average increase in the
size of the hot spots respectively, which as reflected in
the p values, is very significant.
By binning the prostate volume data, it is possible to
show the distributions of the dosimetry parameters graph-
ically, as illustrated in Figure 2, Figure 3, Figure 4 andFigure 7 Distribution of urethra D30values for planned and implanteFigure 5. Visually, this supports the statistical evidence as
a clear increase in the distribution of D90, V150 and
V200 while there is no clear change in the data for V100.
Given that the prostate, as a volume, is a subset of the
PTV it would be expected for the dosimetry results to
be reasonably similar and this is what is shown in
Tables 3 and Table 4. While there is no significant diffe-
rence in the D90 values, there is a significant increase in
V150 and V200 of 4% and 20% respectively, the same
order as for the target.
Organs at risk
As with the prostate and PTV there is a general increase
in the value of the dosimetry parameters used for the
urethra in LDR prostate treatments from the planned
to the implanted treatment. This increase can be seen
in Table 5 while the statistical data in Table 6 illustratesd dosimetry.
Table 7 Mean values for D2cc and D0.1cc for the rectum
along with the associated standard deviations
Dosimetry Parameter Planned St Dev Implanted St Dev
D2cc (Gy) 77.7 18.6 80.0 22.6
D0.1cc (Gy) 145.3 26.6 149.6 30.0
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however, that the changes are reasonably small in the
actual values, of only around 3%.
Figure 6 and Figure 7 clearly illustrate this shifting of
urethral doses to higher levels for the implanted seed
distribution compared to the planned seed distribution.
The rectum dosimetry data given in Tables 7 and
Table 8 show a statistically significant increase in the
values for D0.1cc which is an indicator of the hot spot
dose in the rectum. However, as with the urethra, it
could be argued that the effect of this relatively small
increase of only ~3% might be insignificant. In fact,
compared to the dose distributions of the prostate and
rectum, little clear change is visible in Figure 8 and
Figure 9.
Discussion
Needle misplacement is one common factor responsible
for the loss of prostate coverage between planned and
implanted dosimetry. This observation is confirmed by
clinical studies reporting on source misplacements which
ranged from 0.0 to 1.0 cm due to discrepancy between
planned and achieved needle placement [9]. It is sug-
gested that the adoption of real-time 3D computer plan-
ning system updates during I-125 implants significantly
improves prostate coverage while reducing the doses to
the organs at risk (the V150 for urethra of > 30% was
reduced from 63% to 17% patients) [10].
As outlined earlier, there were insignificant (or very
weakly significant) variations among the primary dosi-
metric parameters (D90 and V100) between planned and
implanted dosimetry. This outcome is to be expected as
D90 and V100 are the dosimetry parameters which are
targeted in the planning process. This is especially evi-
dent with V100 which is not only targeted to be above
98% but has an upper bound of 100%. Thus it would not
be expected to observe large deviations in this parameter
unless the person implanting was completely missing
the target.
Where significant change in dosimetric parameters is
observed however, is in the ‘hotspot’ parameters (eg V150,Table 8 Percent differences and statistics for rectum data
Dosimetry Parameter Mean % Diff t test score P value
D2cc 3.07 2.42 0.0166
D0.1cc 3.00 2.91 0.0042V200) and OAR measures. The increase is indicative of a
general ‘bunching’ of seeds towards clumps. This clump-
ing could be due to the presence of pubic arch and other
obstructions such as calcifications and already deployed
seeds which will cause the path of the needle to be de-
flected. While each deviation of a needle may only be of
the order of a millimetre, over a total implant of 60–90
seeds this could cause significant increases of hotspots, es-
pecially in the urethra which is generally located at the ap-
proximate centre of the prostate.
The most glaring example of increases in hotspots is
typified by the elevated average V200 value of approxi-
mately 20% between planned and implanted dosimetry.
It should be noted that extra seeds are implanted when
needed at the end of the procedure to improve the dos-
imetry if need be. In the majority of cases this is not
required, although in this study group 43% of patients
did have extra seeds implanted. This was due to either:
(1) making up for grossly miss placed seeds (mostly along
superior/inferior direction due to poor seed deployment),
i.e. more than 5mm from planned position, or (2) accoun-
ting for obvious differences in prostate shape (due to
swelling as implant progresses) between planned volume
and implanted volume. The benefit of real-time dose
calculation updates enables the radiation oncologist to
decide if the extra seeds were needed or not. The ave-
rage number of extra seeds implanted was small, i.e. 2.6
(with a range of −1 to 12 extra seeds), and the most com-
mon number (i.e. more than 40% of cases) was 2 seeds.
To put in perspective, the mean total number of seeds
implanted per patient for the study group is 70 seeds.
Therefore, the average 2.6 extra seeds added to 43% of
the patients has a small influence on the overall study
results (approximately < 2%), but is part of the real-time
implant process and can not be discarded from analysis.
It should also be noted that, in general, before extra seeds
are implanted they are added to the real-time plan to see
if they would be of benefit or not to the final dosimetry.
In the case of the OAR these increases in average
doses are of the order of 3% which, while statistically sig-
nificant, are likely to not be considered clinically impor-
tant. It should be noted however that these levels of
increases are clinic specific and influenced by the high
level of experience in performing LDR seed implants by
the urologists/oncologists in question. Thus for a new
practice it is important that some level of live planning
guidance be available in order to account for any errors
in the implantation process.
The first work on real-time dosimetry was conducted
on HDR brachytherapy for advanced prostate cancers
[11,12]. LDR real-time dosimetry followed later, with one
of the first reports being published by Stock and Stone
(2000) [13] on a small cohort of 10 consecutive patients.
Prada and colleagues [2] reported on a real-time dynamic
Figure 8 Distribution of rectal D2cc values for planned and implanted dosimetry.
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replaced, in their practice, the need for post implant
dosimetry. In order to avoid the challenges encountered
during prostate delineation on post implant CT images,
the group has implemented an interactive intra-operative
dose calculation method whereby the treatment plan is
designed on the spot according to anatomical specificities
and limitations, with needles being positioned where
considered most adequate, and not at given coordinates.
The procedure is guided via TRUS and the needle
positions are continuously updated on the Variseed 7.1
(Varian) planning system to reflect the real-time isodose
distributions. The reported results showed good quality
implants, with a median V90 of 98% and low normal
tissue toxicity. Though our implant technique resem-
bles to some extent to the one described above, post
implant dosimetry remains to be part of the procedure
in our centre.Figure 9 Distribution of rectal D0.1cc values for planned and implantWhile the aim of this project was to examine the dif-
ferences in the planned dosimetry and the real-time
updated implant dosimetry, there are more studies loo-
king at dosimetric changes between the two-step proce-
dure (volume study and planning followed weeks later by
implant) and one-step live planning technique. Wilkinson
et al. (2000) [14] have shown the improvements to do-
simetry due to changing from the two-step to the one-
step treatment technique via analysis of post implant
dosimetry. The better dosimetric outcome with one-step
technique can be attributed to the elimination of several
uncertainties regarding patient setup and positioning,
anatomical changes and organ movement. A comprehen-
sive review on the intra-operative (real-time) planning
techniques has analysed the advantages of real-time plan-
ning in overcoming the sources of errors in the two-step
procedures mentioned above [15]. The real-time tracking
of needles, as also confirmed by our study, was shown toed dosimetry.
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action for adjustments, when needed.
Conclusions
This investigation assessed the accuracy of prostate seed
implants by making comparisons between the planned
dosimetry and actual implanted dosimetry. A general in-
crease in the volume of high dose regions were the main
differences observed for the implant dosimetry. This
would be due to some needles being implanted closer
together than planned. Hence, an increase in the size of
hotspots within the prostate was observed, which did
not necessarily have an effect on the size of the 145Gy
isodose volume, as indicated by the small differences ob-
served for V100.
Across the board increases in dose to OAR was also
seen (in some cases significant), however the absolute
changes in the OAR dosimetry were minimal and thus
may not be of clinical concern.
The results show that geographical misses and/or
needle displacements during implant may have repercus-
sions for centres without real-time live planning due to
the resultant dose distribution from the misplaced seeds
not being taken into account.
The overall small changes observed confirms the pre-
cision of the implant technique which RAH has in
place. However the ability to update the plan dosime-
try with real-time planning, for the one step live plan-
ning technique, highlights that the implanted dosimetry
can be improved.
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